Obesity and type 2 diabetes mellitus (T2DM) have become national and global epidemics. The rising prevalence of obesity has dramatically increased the burden of dyslipidemia, specific types of cancer, nonalcoholic fatty liver disease, T2DM and cardiovascular diseases, the leading cause of mortality in the country. Recent studies have highlighted the intimate links between metabolic diseases and adipose tissue inflammation. Adipose inflammation plays an integral role in the development of metabolic syndrome. Adipose-immune interactions can have both positive and negative effects on adipose tissue homeostasis and whole body metabolism. What initiates adipocyte dysfunction and the inflammatory processes in obesity remain an enigma. This research proposal seeks to understand the molecular mechanisms that underlie adipocyte dysfunction and adipose inflammation. We identify fam20c as a novel regulator of adipose tissue inflammation and insulin resistance. Obesity induces expression of fam20c in adipocytes. Conversely, ablation of fam20c in adipocytes ameliorates hyperglycemia. In this proposal, we seek to assess the mechanistic links between insulin resistance and inflammation. We will pursue the following specific aims: 1. Determine the physiological and cellular mechanisms by fam20c regulates energy balance, glucose homeostasis and adipose tissue inflammation. 2. Dissect the molecular mechanism of action of the fam20c kinase in regulating inflammatory gene expression and insulin resistance. 3. We will test the hypothesis that adipose-specific ablation of fam20c can reverse established T2DM. The overall goal of these studies will shed light on how therapies directed against fam20c can be used to restore metabolic health in patients with T2DM.

Public Health Relevance

Obesity and type 2 diabetes have become national public health epidemics with impact on many diseases including certain types of cancer, liver disease and cardiovascular disease. Despite numerous advances in the past decade, there are limited to no proven medical therapies that can reverse or cure diabetes. This proposal aims to develop new therapies that can be used to treat and reverse type 2 diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK121844-02
Application #
9997916
Study Section
Molecular and Cellular Endocrinology Study Section (MCE)
Program Officer
Haft, Carol R
Project Start
2019-08-16
Project End
2024-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
2
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065